{"transactions":[{"id":1128951,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-05-30T17:59:04.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the Company's 2021 Equity Incentive Plan)."}],"balance_after":50000,"derivative":{"exercise_price":0.62,"expiration_date":"2035-05-27","underlying":"Class A Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-25-015039","document":"form4-05302025_090545.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1529708/000141588925015039/form4-05302025_090545.xml","form_type":"4"}},{"id":1328194,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-17T17:00:03.000Z","date":"2024-12-16","kind":"grant","planned":false,"acquired":true,"shares":15423,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $9.44 per share. There is no change to the expiration dates or the vesting schedule of the options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vested as follows: 1/36th of the shares subject to the option vested monthly over three years from June 17, 2021."}],"balance_after":79317,"derivative":{"exercise_price":9.44,"expiration_date":"2031-07-28","underlying":"Class A Common Stock","underlying_shares":15423},"source":{"system":"sec-edgar","filing":"0000950170-24-137313","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1529708/000095017024137313/ownership.xml","form_type":"4"}},{"id":1328193,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-17T17:00:03.000Z","date":"2024-12-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15423,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $9.44 per share. There is no change to the expiration dates or the vesting schedule of the options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vested as follows: 1/36th of the shares subject to the option vested monthly over three years from June 17, 2021."}],"balance_after":0,"derivative":{"exercise_price":2.84,"expiration_date":"2031-07-28","underlying":"Class A Common Stock","underlying_shares":15423},"source":{"system":"sec-edgar","filing":"0000950170-24-137313","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1529708/000095017024137313/ownership.xml","form_type":"4"}},{"id":1328192,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-17T17:00:03.000Z","date":"2024-12-16","kind":"grant","planned":false,"acquired":true,"shares":101276,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $4.11 per share. There is no change to the expiration dates or the vesting schedule of the options."}],"balance_after":101276,"derivative":{"exercise_price":4.11,"exercise_date":"2024-05-25","expiration_date":"2033-05-24","underlying":"Class A Common Stock","underlying_shares":101276},"source":{"system":"sec-edgar","filing":"0000950170-24-137313","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1529708/000095017024137313/ownership.xml","form_type":"4"}},{"id":1328191,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-17T17:00:03.000Z","date":"2024-12-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":101276,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $4.11 per share. There is no change to the expiration dates or the vesting schedule of the options."}],"balance_after":0,"derivative":{"exercise_price":2.84,"exercise_date":"2024-05-25","expiration_date":"2033-05-24","underlying":"Class A Common Stock","underlying_shares":101276},"source":{"system":"sec-edgar","filing":"0000950170-24-137313","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1529708/000095017024137313/ownership.xml","form_type":"4"}},{"id":1497513,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-30T16:10:07.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the Company's 2021 Equity Incentive Plan)."}],"balance_after":50000,"derivative":{"exercise_price":5,"expiration_date":"2034-05-28","underlying":"Class A Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-24-066581","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1529708/000095017024066581/ownership.xml","form_type":"4"}},{"id":1704415,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-19T16:05:19.000Z","date":"2023-12-16","kind":"grant","planned":false,"acquired":true,"shares":15423,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 16, 2023 (the \"Repricing Date\"). Pursuant to\nthe Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's\nCommon Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option vest as follows: 1/36th of the shares subject to the option vest monthly over three years from June 17, 2021."}],"balance_after":15423,"derivative":{"exercise_price":2.84,"expiration_date":"2031-07-28","underlying":"Class A Common Stock","underlying_shares":15423},"source":{"system":"sec-edgar","filing":"0000950170-23-071468","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1529708/000095017023071468/ownership.xml","form_type":"4"}},{"id":1704414,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-19T16:05:19.000Z","date":"2023-12-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15423,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 16, 2023 (the \"Repricing Date\"). Pursuant to\nthe Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's\nCommon Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option vest as follows: 1/36th of the shares subject to the option vest monthly over three years from June 17, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date."}],"balance_after":63894,"derivative":{"exercise_price":9.44,"expiration_date":"2031-07-28","underlying":"Class A Common Stock","underlying_shares":15423},"source":{"system":"sec-edgar","filing":"0000950170-23-071468","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1529708/000095017023071468/ownership.xml","form_type":"4"}},{"id":1704413,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-19T16:05:19.000Z","date":"2023-12-16","kind":"grant","planned":false,"acquired":true,"shares":101276,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 16, 2023 (the \"Repricing Date\"). Pursuant to\nthe Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's\nCommon Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on May 25, 2024, subject to the recipient's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Issuer's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan)."}],"balance_after":101276,"derivative":{"exercise_price":2.84,"expiration_date":"2033-05-24","underlying":"Class A Common Stock","underlying_shares":101276},"source":{"system":"sec-edgar","filing":"0000950170-23-071468","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1529708/000095017023071468/ownership.xml","form_type":"4"}},{"id":1704412,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-19T16:05:19.000Z","date":"2023-12-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":101276,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 16, 2023 (the \"Repricing Date\"). Pursuant to\nthe Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's\nCommon Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on May 25, 2024, subject to the recipient's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Issuer's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan)."}],"balance_after":0,"derivative":{"exercise_price":4.11,"expiration_date":"2033-05-24","underlying":"Class A Common Stock","underlying_shares":101276},"source":{"system":"sec-edgar","filing":"0000950170-23-071468","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1529708/000095017023071468/ownership.xml","form_type":"4"}},{"id":1734249,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-11-20T08:00:07.000Z","date":"2023-11-16","kind":"purchase","planned":false,"acquired":true,"shares":500,"price":1.98,"value":990.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.97 to $2.00, inclusive.\nThe Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full\ninformation regarding the number of shares purchased at each separate price within the range."}],"balance_after":500,"source":{"system":"sec-edgar","filing":"0000950170-23-064982","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1529708/000095017023064982/ownership.xml","form_type":"4"}},{"id":1874319,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-30T20:09:06.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":101276,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan)."}],"balance_after":101276,"derivative":{"exercise_price":4.11,"expiration_date":"2033-05-24","underlying":"Class A Common Stock","underlying_shares":101276},"source":{"system":"sec-edgar","filing":"0001209191-23-033047","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1529708/000120919123033047/doc4.xml","form_type":"4"}},{"id":2252792,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-27T08:30:40.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":41416,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan)."}],"balance_after":41416,"derivative":{"exercise_price":10.89,"expiration_date":"2032-05-24","underlying":"Class A Common Stock","underlying_shares":41416},"source":{"system":"sec-edgar","filing":"0000899243-22-019858","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1529708/000089924322019858/doc4.xml","form_type":"4"}},{"id":2362886,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Deferred Stock Units","published_at":"2022-03-02T21:28:54.000Z","date":"2022-02-28","kind":"exercise","acquired":false,"shares":1630,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"expiration_date":"2022-02-28","underlying":"Common Stock","underlying_shares":1630},"source":{"system":"sec-edgar","filing":"0001225208-22-003865","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822003865/doc4.xml","form_type":"4"}},{"id":2362885,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2022-03-02T21:28:54.000Z","date":"2022-02-28","kind":"tax_withholding","acquired":false,"shares":564,"price":44.17,"value":24911.88,"ownership":{"direct":true},"balance_after":177258,"source":{"system":"sec-edgar","filing":"0001225208-22-003865","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822003865/doc4.xml","form_type":"4"}},{"id":2362884,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2022-03-02T21:28:54.000Z","date":"2022-02-28","kind":"exercise","acquired":true,"shares":1630,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":177822,"source":{"system":"sec-edgar","filing":"0001225208-22-003865","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822003865/doc4.xml","form_type":"4"}},{"id":2376160,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Performance Share Units","published_at":"2022-02-24T21:21:51.000Z","date":"2022-02-22","kind":"grant","acquired":true,"shares":11335,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023."}],"balance_after":11335,"derivative":{"exercise_date":"2023-12-31","expiration_date":"2023-12-31","underlying":"Common Stock","underlying_shares":11335},"source":{"system":"sec-edgar","filing":"0001225208-22-003297","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822003297/doc4.xml","form_type":"4"}},{"id":2380089,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Deferred Stock Units","published_at":"2022-02-23T21:18:14.000Z","date":"2022-02-21","kind":"exercise","acquired":false,"shares":1714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant."}],"balance_after":1714,"derivative":{"expiration_date":"2023-02-21","underlying":"Common Stock","underlying_shares":1714},"source":{"system":"sec-edgar","filing":"0001225208-22-003085","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822003085/doc4.xml","form_type":"4"}},{"id":2380088,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2022-02-23T21:18:14.000Z","date":"2022-02-21","kind":"tax_withholding","acquired":false,"shares":593,"price":42.55,"value":25232.15,"ownership":{"direct":true},"balance_after":176192,"source":{"system":"sec-edgar","filing":"0001225208-22-003085","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822003085/doc4.xml","form_type":"4"}},{"id":2380087,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2022-02-23T21:18:14.000Z","date":"2022-02-21","kind":"exercise","acquired":true,"shares":1714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":176785,"source":{"system":"sec-edgar","filing":"0001225208-22-003085","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822003085/doc4.xml","form_type":"4"}},{"id":2383547,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Deferred Stock Units","published_at":"2022-02-22T21:46:11.000Z","date":"2022-02-18","kind":"exercise","acquired":false,"shares":1779,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant."}],"balance_after":3558,"derivative":{"expiration_date":"2024-02-18","underlying":"Common Stock","underlying_shares":1779},"source":{"system":"sec-edgar","filing":"0001225208-22-002924","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822002924/doc4.xml","form_type":"4"}},{"id":2383546,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Restricted Stock Units","published_at":"2022-02-22T21:46:11.000Z","date":"2022-02-17","kind":"exercise","acquired":false,"shares":2166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant."}],"balance_after":6500,"derivative":{"expiration_date":"2025-02-17","underlying":"Common Stock","underlying_shares":2166},"source":{"system":"sec-edgar","filing":"0001225208-22-002924","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822002924/doc4.xml","form_type":"4"}},{"id":2383545,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2022-02-22T21:46:11.000Z","date":"2022-02-18","kind":"tax_withholding","acquired":false,"shares":616,"price":42.55,"value":26210.8,"ownership":{"direct":true},"balance_after":175071,"source":{"system":"sec-edgar","filing":"0001225208-22-002924","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822002924/doc4.xml","form_type":"4"}},{"id":2383544,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2022-02-22T21:46:11.000Z","date":"2022-02-18","kind":"exercise","acquired":true,"shares":1779,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":175687,"source":{"system":"sec-edgar","filing":"0001225208-22-002924","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822002924/doc4.xml","form_type":"4"}},{"id":2383543,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2022-02-22T21:46:11.000Z","date":"2022-02-17","kind":"tax_withholding","acquired":false,"shares":750,"price":42.83,"value":32122.5,"ownership":{"direct":true},"balance_after":173908,"source":{"system":"sec-edgar","filing":"0001225208-22-002924","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822002924/doc4.xml","form_type":"4"}},{"id":2383542,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2022-02-22T21:46:11.000Z","date":"2022-02-17","kind":"exercise","acquired":true,"shares":2166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":174658,"source":{"system":"sec-edgar","filing":"0001225208-22-002924","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822002924/doc4.xml","form_type":"4"}},{"id":2389869,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-18T01:28:53.000Z","date":"2022-02-16","kind":"grant","acquired":true,"shares":21029,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant."}],"balance_after":21029,"derivative":{"exercise_price":44.19,"expiration_date":"2032-02-16","underlying":"Common Stock","underlying_shares":21029},"source":{"system":"sec-edgar","filing":"0001225208-22-002681","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822002681/doc4.xml","form_type":"4"}},{"id":2389868,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Restricted Stock Units","published_at":"2022-02-18T01:28:53.000Z","date":"2022-02-16","kind":"grant","acquired":true,"shares":7354,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant."}],"balance_after":7354,"derivative":{"expiration_date":"2026-02-16","underlying":"Common Stock","underlying_shares":7354},"source":{"system":"sec-edgar","filing":"0001225208-22-002681","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822002681/doc4.xml","form_type":"4"}},{"id":2389867,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Deferred Stock Units","published_at":"2022-02-18T01:28:53.000Z","date":"2022-02-15","kind":"exercise","acquired":false,"shares":1661,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant."}],"balance_after":1661,"derivative":{"expiration_date":"2023-02-15","underlying":"Common Stock","underlying_shares":1661},"source":{"system":"sec-edgar","filing":"0001225208-22-002681","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822002681/doc4.xml","form_type":"4"}},{"id":2389866,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2022-02-18T01:28:53.000Z","date":"2022-02-15","kind":"tax_withholding","acquired":false,"shares":575,"price":44.01,"value":25305.75,"ownership":{"direct":true},"balance_after":172492,"source":{"system":"sec-edgar","filing":"0001225208-22-002681","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822002681/doc4.xml","form_type":"4"}},{"id":2389865,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2022-02-18T01:28:53.000Z","date":"2022-02-15","kind":"exercise","acquired":true,"shares":1661,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":173067,"source":{"system":"sec-edgar","filing":"0001225208-22-002681","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822002681/doc4.xml","form_type":"4"}},{"id":2409897,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-02-07T21:43:30.000Z","date":"2022-02-03","kind":"other","acquired":true,"shares":11017,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Received in kind pro rata distribution from VH Rani, LP. to its limited partners."}],"balance_after":11017,"source":{"system":"sec-edgar","filing":"0001209191-22-007638","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1529708/000120919122007638/doc4.xml","form_type":"4"}},{"id":2455116,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Performance Share Units","published_at":"2022-01-03T21:52:56.000Z","date":"2022-01-01","kind":"exercise","acquired":false,"shares":6175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021."}],"balance_after":0,"derivative":{"exercise_date":"2021-12-31","expiration_date":"2021-12-31","underlying":"Common Stock","underlying_shares":6175},"source":{"system":"sec-edgar","filing":"0001225208-22-000115","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822000115/doc4.xml","form_type":"4"}},{"id":2455115,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2022-01-03T21:52:56.000Z","date":"2022-01-01","kind":"tax_withholding","acquired":false,"shares":2346,"price":42.48,"value":99658.08,"ownership":{"direct":true},"balance_after":171406,"source":{"system":"sec-edgar","filing":"0001225208-22-000115","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822000115/doc4.xml","form_type":"4"}},{"id":2455114,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2022-01-03T21:52:56.000Z","date":"2022-01-01","kind":"exercise","acquired":true,"shares":6175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":173752,"source":{"system":"sec-edgar","filing":"0001225208-22-000115","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822000115/doc4.xml","form_type":"4"}},{"id":2615983,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-04T20:37:12.000Z","date":"2021-08-02","kind":"grant","acquired":true,"shares":34965,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on August 2, 2022, the first anniversary of the date of grant."}],"balance_after":34965,"derivative":{"exercise_price":45.88,"expiration_date":"2031-08-02","underlying":"Common Stock","underlying_shares":34965},"source":{"system":"sec-edgar","filing":"0001225208-21-011122","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821011122/doc4.xml","form_type":"4"}},{"id":2687683,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2021-06-02T20:19:26.000Z","date":"2021-05-28","kind":"sale","acquired":false,"shares":78192,"price":42.5931,"value":3330439.6752,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $42.51 to $42.67, inclusive. The reporting person undertakes to provide upon request by theU.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":166869,"source":{"system":"sec-edgar","filing":"0001225208-21-008788","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821008788/doc4.xml","form_type":"4"}},{"id":2822971,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Deferred Stock Units","published_at":"2021-03-02T21:16:19.000Z","date":"2021-02-28","kind":"exercise","acquired":false,"shares":1629,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant."}],"balance_after":1630,"derivative":{"expiration_date":"2022-02-28","underlying":"Common Stock","underlying_shares":1629},"source":{"system":"sec-edgar","filing":"0001225208-21-004223","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821004223/doc4.xml","form_type":"4"}},{"id":2822970,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2021-03-02T21:16:19.000Z","date":"2021-02-28","kind":"tax_withholding","acquired":false,"shares":564,"price":38.78,"value":21871.92,"ownership":{"direct":true},"balance_after":245061,"source":{"system":"sec-edgar","filing":"0001225208-21-004223","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821004223/doc4.xml","form_type":"4"}},{"id":2822969,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2021-03-02T21:16:19.000Z","date":"2021-02-28","kind":"exercise","acquired":true,"shares":1629,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":245625,"source":{"system":"sec-edgar","filing":"0001225208-21-004223","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821004223/doc4.xml","form_type":"4"}},{"id":2841164,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Performance Share Units","published_at":"2021-02-23T22:13:44.000Z","date":"2021-02-22","kind":"grant","acquired":true,"shares":6303,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"shares","element":"transactionShares","label":"F5","text":"On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022."}],"balance_after":6303,"derivative":{"exercise_date":"2022-12-31","expiration_date":"2022-12-31","underlying":"Common Stock","underlying_shares":6303},"source":{"system":"sec-edgar","filing":"0001225208-21-003524","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821003524/doc4.xml","form_type":"4"}},{"id":2841163,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Deferred Stock Units","published_at":"2021-02-23T22:13:44.000Z","date":"2021-02-22","kind":"exercise","acquired":false,"shares":1883,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"expiration_date":"2021-02-22","underlying":"Common Stock","underlying_shares":1883},"source":{"system":"sec-edgar","filing":"0001225208-21-003524","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821003524/doc4.xml","form_type":"4"}},{"id":2841162,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Deferred Stock Units","published_at":"2021-02-23T22:13:44.000Z","date":"2021-02-21","kind":"exercise","acquired":false,"shares":1713,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant."}],"balance_after":3428,"derivative":{"expiration_date":"2023-02-21","underlying":"Common Stock","underlying_shares":1713},"source":{"system":"sec-edgar","filing":"0001225208-21-003524","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821003524/doc4.xml","form_type":"4"}},{"id":2841161,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2021-02-23T22:13:44.000Z","date":"2021-02-22","kind":"tax_withholding","acquired":false,"shares":652,"price":39.2,"value":25558.4,"ownership":{"direct":true},"balance_after":243996,"source":{"system":"sec-edgar","filing":"0001225208-21-003524","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821003524/doc4.xml","form_type":"4"}},{"id":2841160,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2021-02-23T22:13:44.000Z","date":"2021-02-22","kind":"exercise","acquired":true,"shares":1883,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":244648,"source":{"system":"sec-edgar","filing":"0001225208-21-003524","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821003524/doc4.xml","form_type":"4"}},{"id":2841159,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2021-02-23T22:13:44.000Z","date":"2021-02-21","kind":"tax_withholding","acquired":false,"shares":593,"price":38.03,"value":22551.79,"ownership":{"direct":true},"balance_after":242765,"source":{"system":"sec-edgar","filing":"0001225208-21-003524","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821003524/doc4.xml","form_type":"4"}},{"id":2841158,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2021-02-23T22:13:44.000Z","date":"2021-02-21","kind":"exercise","acquired":true,"shares":1713,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":243358,"source":{"system":"sec-edgar","filing":"0001225208-21-003524","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821003524/doc4.xml","form_type":"4"}},{"id":2847405,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Deferred Stock Units","published_at":"2021-02-19T21:21:33.000Z","date":"2021-02-18","kind":"exercise","acquired":false,"shares":1778,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant."}],"balance_after":5337,"derivative":{"expiration_date":"2024-02-18","underlying":"Common Stock","underlying_shares":1778},"source":{"system":"sec-edgar","filing":"0001225208-21-003178","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821003178/doc4.xml","form_type":"4"}},{"id":2847404,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-19T21:21:33.000Z","date":"2021-02-17","kind":"grant","acquired":true,"shares":27873,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant."}],"balance_after":27873,"derivative":{"exercise_price":37.5,"expiration_date":"2031-02-17","underlying":"Common Stock","underlying_shares":27873},"source":{"system":"sec-edgar","filing":"0001225208-21-003178","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821003178/doc4.xml","form_type":"4"}},{"id":2847403,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Restricted Stock Units","published_at":"2021-02-19T21:21:33.000Z","date":"2021-02-17","kind":"grant","acquired":true,"shares":8666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant."}],"balance_after":8666,"derivative":{"expiration_date":"2025-02-17","underlying":"Common Stock","underlying_shares":8666},"source":{"system":"sec-edgar","filing":"0001225208-21-003178","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821003178/doc4.xml","form_type":"4"}},{"id":2847402,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2021-02-19T21:21:33.000Z","date":"2021-02-18","kind":"tax_withholding","acquired":false,"shares":615,"price":37.52,"value":23074.8,"ownership":{"direct":true},"balance_after":241645,"source":{"system":"sec-edgar","filing":"0001225208-21-003178","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821003178/doc4.xml","form_type":"4"}},{"id":2847401,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2021-02-19T21:21:33.000Z","date":"2021-02-18","kind":"exercise","acquired":true,"shares":1778,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":242260,"source":{"system":"sec-edgar","filing":"0001225208-21-003178","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821003178/doc4.xml","form_type":"4"}},{"id":2856235,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Deferred Stock Units","published_at":"2021-02-17T21:16:00.000Z","date":"2021-02-15","kind":"exercise","acquired":false,"shares":1661,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant."}],"balance_after":3322,"derivative":{"expiration_date":"2023-02-15","underlying":"Common Stock","underlying_shares":1661},"source":{"system":"sec-edgar","filing":"0001225208-21-002706","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821002706/doc4.xml","form_type":"4"}},{"id":2856234,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2021-02-17T21:16:00.000Z","date":"2021-02-15","kind":"tax_withholding","acquired":false,"shares":575,"price":38.39,"value":22074.25,"ownership":{"direct":true},"balance_after":240482,"source":{"system":"sec-edgar","filing":"0001225208-21-002706","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821002706/doc4.xml","form_type":"4"}},{"id":2856233,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2021-02-17T21:16:00.000Z","date":"2021-02-15","kind":"exercise","acquired":true,"shares":1661,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":241057,"source":{"system":"sec-edgar","filing":"0001225208-21-002706","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821002706/doc4.xml","form_type":"4"}},{"id":2867581,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2021-02-11T22:47:28.000Z","date":"2021-02-10","kind":"tax_withholding","acquired":false,"shares":2240,"price":38.85,"value":87024.0,"ownership":{"direct":true},"balance_after":239396,"source":{"system":"sec-edgar","filing":"0001225208-21-002243","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821002243/doc4.xml","form_type":"4"}},{"id":2867580,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2021-02-11T22:47:28.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":6477,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 15, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2020 and subject to the completion of the concurrent three-year individual service period. On February 9, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied."}],"balance_after":241636,"source":{"system":"sec-edgar","filing":"0001225208-21-002243","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821002243/doc4.xml","form_type":"4"}},{"id":2923250,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Performance Share Units","published_at":"2021-01-05T21:16:21.000Z","date":"2021-01-01","kind":"exercise","acquired":false,"shares":9791,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2020."}],"balance_after":0,"derivative":{"exercise_date":"2020-12-31","expiration_date":"2020-12-31","underlying":"Common Stock","underlying_shares":9791},"source":{"system":"sec-edgar","filing":"0001225208-21-000229","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821000229/doc4.xml","form_type":"4"}},{"id":2923249,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2021-01-05T21:16:21.000Z","date":"2021-01-01","kind":"tax_withholding","acquired":false,"shares":3625,"price":35.95,"value":130318.75,"ownership":{"direct":true},"balance_after":235159,"source":{"system":"sec-edgar","filing":"0001225208-21-000229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821000229/doc4.xml","form_type":"4"}},{"id":2923248,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2021-01-05T21:16:21.000Z","date":"2021-01-01","kind":"exercise","acquired":true,"shares":9791,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2020."}],"balance_after":238784,"source":{"system":"sec-edgar","filing":"0001225208-21-000229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520821000229/doc4.xml","form_type":"4"}},{"id":3044089,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-31T20:10:09.000Z","date":"2020-08-28","kind":"exercise","acquired":false,"shares":6851,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":17.26,"expiration_date":"2026-02-22","underlying":"Common Stock","underlying_shares":6851},"source":{"system":"sec-edgar","filing":"0001225208-20-011096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820011096/doc4.xml","form_type":"4"}},{"id":3044088,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2020-08-31T20:10:09.000Z","date":"2020-08-28","kind":"sale","acquired":false,"shares":38000,"price":40.4517,"value":1537164.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $40.44 to $40.47, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":228993,"source":{"system":"sec-edgar","filing":"0001225208-20-011096","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820011096/doc4.xml","form_type":"4"}},{"id":3044087,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2020-08-31T20:10:09.000Z","date":"2020-08-28","kind":"exercise","acquired":true,"shares":6851,"price":17.26,"value":118248.26,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":266993,"source":{"system":"sec-edgar","filing":"0001225208-20-011096","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820011096/doc4.xml","form_type":"4"}},{"id":3235058,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-03T21:15:02.000Z","date":"2020-03-02","kind":"exercise","acquired":false,"shares":9623,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":16.31,"expiration_date":"2025-02-23","underlying":"Common Stock","underlying_shares":9623},"source":{"system":"sec-edgar","filing":"0001225208-20-004163","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820004163/doc4.xml","form_type":"4"}},{"id":3235057,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Deferred Stock Units","published_at":"2020-03-03T21:15:02.000Z","date":"2020-02-28","kind":"exercise","acquired":false,"shares":1629,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant."}],"balance_after":3259,"derivative":{"expiration_date":"2022-02-28","underlying":"Common Stock","underlying_shares":1629},"source":{"system":"sec-edgar","filing":"0001225208-20-004163","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820004163/doc4.xml","form_type":"4"}},{"id":3235056,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2020-03-03T21:15:02.000Z","date":"2020-03-02","kind":"sale","acquired":false,"shares":16763,"price":37.4744,"value":628183.3672,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $37.35 to $37.655, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":259591,"source":{"system":"sec-edgar","filing":"0001225208-20-004163","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820004163/doc4.xml","form_type":"4"}},{"id":3235055,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2020-03-03T21:15:02.000Z","date":"2020-03-02","kind":"exercise","acquired":true,"shares":9623,"price":16.31,"value":156951.13,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":276354,"source":{"system":"sec-edgar","filing":"0001225208-20-004163","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820004163/doc4.xml","form_type":"4"}},{"id":3235054,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2020-03-03T21:15:02.000Z","date":"2020-02-28","kind":"tax_withholding","acquired":false,"shares":808,"price":37.39,"value":30211.12,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":266731,"source":{"system":"sec-edgar","filing":"0001225208-20-004163","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820004163/doc4.xml","form_type":"4"}},{"id":3235053,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2020-03-03T21:15:02.000Z","date":"2020-02-28","kind":"exercise","acquired":true,"shares":1629,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":267539,"source":{"system":"sec-edgar","filing":"0001225208-20-004163","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820004163/doc4.xml","form_type":"4"}},{"id":3247298,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Performance Share Units","published_at":"2020-02-26T21:33:19.000Z","date":"2020-02-24","kind":"grant","acquired":true,"shares":6175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2021."}],"balance_after":6175,"derivative":{"exercise_date":"2021-12-31","expiration_date":"2021-12-31","underlying":"Common Stock","underlying_shares":6175},"source":{"system":"sec-edgar","filing":"0001225208-20-003569","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820003569/doc4.xml","form_type":"4"}},{"id":3254572,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Deferred Stock Units","published_at":"2020-02-24T22:13:00.000Z","date":"2020-02-23","kind":"exercise","acquired":false,"shares":1840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"expiration_date":"2020-02-23","underlying":"Common Stock","underlying_shares":1840},"source":{"system":"sec-edgar","filing":"0001225208-20-003296","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820003296/doc4.xml","form_type":"4"}},{"id":3254571,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Deferred Stock Units","published_at":"2020-02-24T22:13:00.000Z","date":"2020-02-22","kind":"exercise","acquired":false,"shares":1883,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant."}],"balance_after":1883,"derivative":{"expiration_date":"2021-02-22","underlying":"Common Stock","underlying_shares":1883},"source":{"system":"sec-edgar","filing":"0001225208-20-003296","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820003296/doc4.xml","form_type":"4"}},{"id":3254570,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Deferred Stock Units","published_at":"2020-02-24T22:13:00.000Z","date":"2020-02-21","kind":"exercise","acquired":false,"shares":1713,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant."}],"balance_after":5141,"derivative":{"expiration_date":"2023-02-21","underlying":"Common Stock","underlying_shares":1713},"source":{"system":"sec-edgar","filing":"0001225208-20-003296","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820003296/doc4.xml","form_type":"4"}},{"id":3254569,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2020-02-24T22:13:00.000Z","date":"2020-02-23","kind":"tax_withholding","acquired":false,"shares":913,"price":42.62,"value":38912.06,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":265910,"source":{"system":"sec-edgar","filing":"0001225208-20-003296","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820003296/doc4.xml","form_type":"4"}},{"id":3254568,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2020-02-24T22:13:00.000Z","date":"2020-02-23","kind":"exercise","acquired":true,"shares":1840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":266823,"source":{"system":"sec-edgar","filing":"0001225208-20-003296","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820003296/doc4.xml","form_type":"4"}},{"id":3254567,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2020-02-24T22:13:00.000Z","date":"2020-02-22","kind":"tax_withholding","acquired":false,"shares":934,"price":42.62,"value":39807.08,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":264983,"source":{"system":"sec-edgar","filing":"0001225208-20-003296","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820003296/doc4.xml","form_type":"4"}},{"id":3254566,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2020-02-24T22:13:00.000Z","date":"2020-02-22","kind":"exercise","acquired":true,"shares":1883,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":265917,"source":{"system":"sec-edgar","filing":"0001225208-20-003296","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820003296/doc4.xml","form_type":"4"}},{"id":3254565,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2020-02-24T22:13:00.000Z","date":"2020-02-21","kind":"tax_withholding","acquired":false,"shares":850,"price":42.62,"value":36227.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":264034,"source":{"system":"sec-edgar","filing":"0001225208-20-003296","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820003296/doc4.xml","form_type":"4"}},{"id":3254564,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2020-02-24T22:13:00.000Z","date":"2020-02-21","kind":"exercise","acquired":true,"shares":1713,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":264884,"source":{"system":"sec-edgar","filing":"0001225208-20-003296","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820003296/doc4.xml","form_type":"4"}},{"id":3264761,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-19T22:32:11.000Z","date":"2020-02-18","kind":"grant","acquired":true,"shares":26548,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant."}],"balance_after":26548,"derivative":{"exercise_price":42.16,"expiration_date":"2030-02-18","underlying":"Common Stock","underlying_shares":26548},"source":{"system":"sec-edgar","filing":"0001225208-20-002841","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820002841/doc4.xml","form_type":"4"}},{"id":3264760,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Deferred Stock Units","published_at":"2020-02-19T22:32:11.000Z","date":"2020-02-18","kind":"grant","acquired":true,"shares":7115,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant."}],"balance_after":7115,"derivative":{"expiration_date":"2024-02-18","underlying":"Common Stock","underlying_shares":7115},"source":{"system":"sec-edgar","filing":"0001225208-20-002841","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820002841/doc4.xml","form_type":"4"}},{"id":3268228,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Deferred Stock Units","published_at":"2020-02-18T21:19:09.000Z","date":"2020-02-15","kind":"exercise","acquired":false,"shares":1661,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant."}],"balance_after":4983,"derivative":{"expiration_date":"2023-02-15","underlying":"Common Stock","underlying_shares":1661},"source":{"system":"sec-edgar","filing":"0001225208-20-002614","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820002614/doc4.xml","form_type":"4"}},{"id":3268227,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2020-02-18T21:19:09.000Z","date":"2020-02-15","kind":"tax_withholding","acquired":false,"shares":824,"price":42.31,"value":34863.44,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":263171,"source":{"system":"sec-edgar","filing":"0001225208-20-002614","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820002614/doc4.xml","form_type":"4"}},{"id":3268226,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2020-02-18T21:19:09.000Z","date":"2020-02-15","kind":"exercise","acquired":true,"shares":1661,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":263995,"source":{"system":"sec-edgar","filing":"0001225208-20-002614","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820002614/doc4.xml","form_type":"4"}},{"id":3268225,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2020-02-18T21:19:09.000Z","date":"2020-02-14","kind":"tax_withholding","acquired":false,"shares":6300,"price":42.31,"value":266553.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":262334,"source":{"system":"sec-edgar","filing":"0001225208-20-002614","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820002614/doc4.xml","form_type":"4"}},{"id":3268224,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2020-02-18T21:19:09.000Z","date":"2020-02-14","kind":"grant","acquired":true,"shares":13440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2019 and subject to the completion of the concurrent three-year individual service period. On February 14, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":268634,"source":{"system":"sec-edgar","filing":"0001225208-20-002614","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820002614/doc4.xml","form_type":"4"}},{"id":3293236,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-04T21:21:00.000Z","date":"2020-02-03","kind":"exercise","acquired":false,"shares":9623,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant."}],"balance_after":9623,"derivative":{"exercise_price":16.31,"expiration_date":"2025-02-23","underlying":"Common Stock","underlying_shares":9623},"source":{"system":"sec-edgar","filing":"0001225208-20-001554","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820001554/doc4.xml","form_type":"4"}},{"id":3293235,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2020-02-04T21:21:00.000Z","date":"2020-02-03","kind":"sale","acquired":false,"shares":9623,"price":42.17,"value":405801.91,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":255194,"source":{"system":"sec-edgar","filing":"0001225208-20-001554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820001554/doc4.xml","form_type":"4"}},{"id":3293234,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2020-02-04T21:21:00.000Z","date":"2020-02-03","kind":"exercise","acquired":true,"shares":9623,"price":16.31,"value":156951.13,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":264817,"source":{"system":"sec-edgar","filing":"0001225208-20-001554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820001554/doc4.xml","form_type":"4"}},{"id":3319961,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2020-01-06T21:12:36.000Z","date":"2020-01-03","kind":"sale","acquired":false,"shares":5025,"price":44.7277,"value":224756.6925,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $44.44 to $45.02, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":255194,"source":{"system":"sec-edgar","filing":"0001225208-20-000515","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820000515/doc4.xml","form_type":"4"}},{"id":3324868,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-03T21:20:53.000Z","date":"2020-01-02","kind":"exercise","acquired":false,"shares":3007,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":13.08,"expiration_date":"2024-02-24","underlying":"Common Stock","underlying_shares":3007},"source":{"system":"sec-edgar","filing":"0001225208-20-000299","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820000299/doc4.xml","form_type":"4"}},{"id":3324867,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-03T21:20:53.000Z","date":"2020-01-02","kind":"exercise","acquired":false,"shares":6616,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant."}],"balance_after":19246,"derivative":{"exercise_price":16.31,"expiration_date":"2025-02-23","underlying":"Common Stock","underlying_shares":6616},"source":{"system":"sec-edgar","filing":"0001225208-20-000299","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820000299/doc4.xml","form_type":"4"}},{"id":3324866,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Performance Share Units","published_at":"2020-01-03T21:20:53.000Z","date":"2020-01-01","kind":"exercise","acquired":false,"shares":7950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The Performance Share Units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The Performance Share Units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The Performance Share Units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2019."}],"balance_after":0,"derivative":{"exercise_date":"2019-12-31","expiration_date":"2019-12-31","underlying":"Common Stock","underlying_shares":7950},"source":{"system":"sec-edgar","filing":"0001225208-20-000299","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820000299/doc4.xml","form_type":"4"}},{"id":3324865,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2020-01-03T21:20:53.000Z","date":"2020-01-02","kind":"sale","acquired":false,"shares":9623,"price":45.3304,"value":436214.4392,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $45.21 to $45.55, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":260219,"source":{"system":"sec-edgar","filing":"0001225208-20-000299","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820000299/doc4.xml","form_type":"4"}},{"id":3324864,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2020-01-03T21:20:53.000Z","date":"2020-01-02","kind":"exercise","acquired":true,"shares":3007,"price":13.08,"value":39331.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":269842,"source":{"system":"sec-edgar","filing":"0001225208-20-000299","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820000299/doc4.xml","form_type":"4"}},{"id":3324863,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2020-01-03T21:20:53.000Z","date":"2020-01-02","kind":"exercise","acquired":true,"shares":6616,"price":16.31,"value":107906.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":266835,"source":{"system":"sec-edgar","filing":"0001225208-20-000299","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820000299/doc4.xml","form_type":"4"}},{"id":3324862,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2020-01-03T21:20:53.000Z","date":"2020-01-01","kind":"tax_withholding","acquired":false,"shares":2925,"price":45.22,"value":132268.5,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":260219,"source":{"system":"sec-edgar","filing":"0001225208-20-000299","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820000299/doc4.xml","form_type":"4"}},{"id":3324861,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2020-01-03T21:20:53.000Z","date":"2020-01-01","kind":"exercise","acquired":true,"shares":7950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The Performance Share Units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2019."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":263144,"source":{"system":"sec-edgar","filing":"0001225208-20-000299","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520820000299/doc4.xml","form_type":"4"}},{"id":3351503,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-05T21:21:08.000Z","date":"2019-12-04","kind":"exercise","acquired":false,"shares":9623,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant."}],"balance_after":3007,"derivative":{"exercise_price":13.08,"expiration_date":"2024-02-24","underlying":"Common Stock","underlying_shares":9623},"source":{"system":"sec-edgar","filing":"0001225208-19-015300","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520819015300/doc4.xml","form_type":"4"}},{"id":3351502,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":79065,"kind":"person","name":"Nanavaty Maulik","position":1,"cik":"0001529708","reported_name":"Nanavaty Maulik","relationship":{"officer":true,"officer_title":"SVP & Pres, Neuromodulation"}}],"security":"Common Stock","published_at":"2019-12-05T21:21:08.000Z","date":"2019-12-04","kind":"sale","acquired":false,"shares":9623,"price":42.8881,"value":412712.1863,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $42.74 to $43.01, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":255194,"source":{"system":"sec-edgar","filing":"0001225208-19-015300","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520819015300/doc4.xml","form_type":"4"}}],"next_cursor":"2019-12-05T21:21:08.000000Z,3351502"}